OVM 300
Alternative Names: OVM-300Latest Information Update: 28 Mar 2024
At a glance
- Originator Oxford Vacmedix
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 31 Dec 2022 Early research in Cancer in the UK (Parenteral) (Oxford Vacmedix pipeline, March 2024)